RA CAPITAL MANAGEMENT, L.P.

October 15, 2026

Vor Biopharma Phase 3 data draws valuation focus. Recent analysis suggests Vor Biopharma may be undervalued as attention shifts to its Phase 3 data for generalized myasthenia gravis. This clinical milestone is central to the stock's current narrative, with analysts maintaining a wide range of price targets. The company's low trailing P/E ratio provides additional context for its current valuation relative to its 52-week trading range.

September 7, 2026

Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.

October 16, 2026

Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.

September 7, 2026

Septerna Schedules Upcoming Investor Conference Appearances. Septerna announced plans to participate in upcoming investor conferences. Such events are routine for publicly traded companies and provide opportunities for management to engage with institutional investors and analysts. The conferences may include presentations and one-on-one meetings, though no specific details about agenda topics were disclosed.

September 25, 2026

ARTV Announces Oral Presentation of AlloNK Data at Sjögren’s Symposium. Artiva Biotherapeutics will give an oral presentation of its AlloNK® clinical data at the 17th International Symposium on Sjögren’s Disease. The talk focuses on early results from a study in patients with this autoimmune disorder. The data could influence how investors view the company’s therapeutic pipeline. The presentation is a milestone before any formal publication or regulatory filing.

October 3, 2026

Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.

October 14, 2026

Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial. Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.

September 25, 2026

Freenome highlights CRC screening market potential. Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.

October 8, 2026

No Relevant News for HOWL in Last Week. The only news item in the last week concerns HALO's expanded collaboration with ARGX. This development does not involve Werewolf Therapeutics, so it has no direct impact on HOWL's operations or outlook. Investors may focus on the company's own pipeline and financials for guidance.

October 13, 2026

Rodman & Renshaw initiates coverage on Hemab Therapeutics. Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.

September 25, 2026

Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program. The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.

September 27, 2026

Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.

October 15, 2026

Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.

September 29, 2026

Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.

October 13, 2026

PRLD announces collaboration and supply deal with Eli Lilly. Prelude Therapeutics disclosed a collaboration and supply agreement with Eli Lilly. The arrangement will have Prelude provide its CDK4/6 inhibitor abemaciclib and oral estrogen receptor antagonist imlunestrant for Lilly‑led clinical trials. Partnering with a large pharmaceutical company may expand Prelude's development pipeline and potential revenue sources. The stock is currently near its long‑term support level.

October 12, 2026

Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.

October 15, 2026

Wave Life Sciences to Present at Chardan Healthcare Conference. Wave Life Sciences announced it will present at Chardan’s 10th Annual Healthcare Conference. The presentation offers a chance to discuss recent developments and pipeline progress with investors and industry peers. This exposure arrives while the stock is near a key support level, and observers may look for any new information that could affect sentiment.

October 13, 2026

BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.

September 25, 2026

Evommune to Present Phase 2a Data for EVO301 at EADV Congress. Evommune will present late‑breaker Phase 2a results for its atopic dermatitis drug EVO301 at the European Academy of Dermatology & Venereology Congress. The presentation follows a setback with its earlier candidate EVO756, shifting focus to the more promising EVO301. The company’s pipeline reset underscores the importance of these data for its future prospects.

September 7, 2026

SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.